[Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?]

Korean J Gastroenterol. 2014 May;63(5):329-32. doi: 10.4166/kjg.2014.63.5.329.
[Article in Korean]
No abstract available

Publication types

  • Comment

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Carcinoma, Hepatocellular / virology*
  • Female
  • Hepatitis B Surface Antigens / blood*
  • Hepatitis B, Chronic / blood*
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Liver Neoplasms / virology*
  • Male

Substances

  • Antiviral Agents
  • Hepatitis B Surface Antigens